Revance Therapeutics, Inc. vs. Medy-Tox, Inc.
Explore the PTAB proceeding IPR2021-01203 filed by Revance Therapeutics, Inc. on 2021-07-01. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2021-01203
Filing Date
2021-07-01
Accorded Filing Date
2021-07-01
Institution Decision Date
2022-01-19
Last Modified Date
2022-09-17
Proceeding Type
IPR
Termination Date
2022-01-19
Trial Status
Institution Denied
Parties & Counsel
Petitioner
Revance Therapeutics, Inc.
Represented By
Ellison, Eldora et alPatent Owner / Respondent
Medy-Tox, Inc.
Represented By
Gates, Edward et alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
1 Total
Proceeding Status
Institution Denied
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 36373 | Allan Brookes | +1 508-733-3757 |
| 44075 | Portia Chen | +1 847-937-8272 |
| 44554 | Matthew Brady | +1 714-246-4788 |
| 46652 | Stephen D'Amico | +1 224-440-7242 |
| 46789 | Mark Hyman | +1 847-937-8941 |
| 47413 | Eric Baude | +1 847-938-8389 |
| 47717 | Renee Kosslak | +1 650-454-2338 |
| 48591 | Tara Seshadri | +1 508-688-8058 |
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ Radar 8 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 9,480,731 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,143,728 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,590,212 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,596,673 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,957,741 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 12,377,137 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2025038746 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2013619154 | US Continuation / Sibling | View Official Patent → |
Revance Therapeutics, Inc. v. Medy-Tox, Inc.
Galderma S.A. et al. v. Medy-Tox, Inc. et al.